Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (NCT05358249)

🧪 Interventions in This Study

• JDQ443 (DRUG)
• trametinib (DRUG)
• Ribociclib (DRUG)
• cetuximab (BIOLOGICAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (13 Sites)

• Massachusetts General Hospital — Boston, Massachusetts
• Dana Farber Cancer Institute — Boston, Massachusetts
• NYU School of Medicine — New York, New York
• Novartis Investigative Site — Leuven,
• Novartis Investigative Site — Bordeaux,
• Novartis Investigative Site — Lyon,
• Novartis Investigative Site — Freiburg im Breisgau, Baden-Wurttemberg
• Novartis Investigative Site — Milan, MI
• Novartis Investigative Site — Singapore,
• Novartis Investigative Site — Seoul,
• Novartis Investigative Site — Barcelona,
• Novartis Investigative Site — Madrid,
• Novartis Investigative Site — Madrid,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in KRAS G12C Mutant Solid Tumors

• Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation — Atlanta, Georgia

Explore by condition: All KRAS G12C Mutant Solid Tumors clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.